Alkermes (NASDAQ:ALKS) Posts Earnings Results, Beats Estimates By $0.21 EPS

Share on StockTwits

Alkermes (NASDAQ:ALKS) announced its quarterly earnings results on Thursday, April 25th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21, Briefing.com reports. Alkermes had a negative net margin of 15.86% and a negative return on equity of 2.08%. The firm had revenue of $223.10 million for the quarter, compared to analysts’ expectations of $218.84 million. During the same period in the previous year, the company posted ($0.09) earnings per share. Alkermes’s revenue was down .9% compared to the same quarter last year. Alkermes updated its FY19 guidance to $0.25-0.43 EPS.

ALKS stock opened at $24.85 on Friday. Alkermes has a fifty-two week low of $24.81 and a fifty-two week high of $51.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.65 and a current ratio of 2.94.

A number of research firms have recently commented on ALKS. Zacks Investment Research raised shares of Alkermes from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Monday, April 8th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Alkermes in a research report on Wednesday, April 10th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. TheStreet raised shares of Alkermes from a “d” rating to a “c-” rating in a research report on Tuesday, February 19th. Finally, BidaskClub cut shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Six analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $40.50.

In other Alkermes news, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $33.48, for a total value of $33,480.00. Following the completion of the sale, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $267,840. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard F. Pops sold 60,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $33.32, for a total transaction of $1,999,200.00. Following the completion of the sale, the director now directly owns 760,604 shares of the company’s stock, valued at $25,343,325.28. The disclosure for this sale can be found here. Insiders sold 162,373 shares of company stock valued at $5,362,950 in the last ninety days. Corporate insiders own 4.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by Tech Know Bits and is the sole property of of Tech Know Bits. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://techknowbits.com/2019/05/19/alkermes-alks-announces-earnings-results.html.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Recommended Story: Trading based on a resistance level

Earnings History for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.